Inside A Phase III Disappointment: Santhera Reduced Target Population, Now Needs Another Trial

FDA seemed on board with Swiss drugmaker's plans for study of Duchenne muscular dystrophy candidate Raxone, but didn't look too kindly on firm's decision to drop subjects using concomitant glucocorticoids.